Skip to content
drillr.ai
Sign up

CELG-RI

BRISTOL MYERS SQUIBB CO

NYSE · Healthcare · Drug Manufacturers - General · US

Also listed · BMY →CELG/RI →
$0.11
+0.00%
Ask drillr

  • Sep 30, 2026, 21:32 UTC

    The U.S. Food and Drug Administration approved an expanded indication for Bristol Myers Squibb's CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients.

    Source:

  • Sep 30, 2026, 10:26 UTC

    China's National Medical Products Administration granted conditional approval via priority review for Bristol-Myers Squibb Pharma EEIG's Class 1 innovative drug ibodutamide hydrochloride capsules (brand name Zanfu) for treating adults with multiple myeloma who have received at least one prior line of therapy.

  • Sep 23, 2026, 22:00 UTC

    Bristol Myers Squibb confirmed 265 additional layoffs in New Jersey on a rolling basis starting in December, bringing its 2026 New Jersey layoffs to 718 workers as part of a plan to trim $2 billion by 2027.

    Source:

  • Sep 23, 2026, 17:45 UTC

    AbbVie, Astex Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson, and Takeda jointly trained the federated AI model AISB-1-Fed on more than 20,000 proprietary protein–ligand structures in collaboration with Columbia University's AlQuraishi lab, achieving 52.1% high-quality interface predictions versus 35.6% for OpenFold3 Preview 2 and 40.9% for Boltz-2.

    Source:

  • Sep 21, 2026, 20:17 UTC

    Travere Therapeutics appointed Bradley L. Campbell as President and Chief Executive Officer effective December 1, 2026.

  • Sep 18, 2026, 10:59 UTC

    Bristol Myers Squibb announced it will report its third-quarter 2026 results on October 29, 2026.

    Source:

  • Sep 17, 2026, 20:17 UTC

    Faeth Therapeutics, Inc. appointed Dr. Karen Vousden as a Class II director and member of its Compensation Committee, effective September 11, 2026, with an option grant of 25,000 shares under the 2026 Equity Incentive Plan.

  • Sep 17, 2026, 10:59 UTC

    Bristol Myers Squibb presented two-year data showing durable efficacy and consistent safety of Sotyktu (deucravacitinib) in adults with psoriatic arthritis.

    Source:

  • Sep 16, 2026, 10:59 UTC

    Bristol-Myers Squibb Company announced a quarterly dividend of $0.63 per share.

    Source:

  • Sep 16, 2026, 10:59 UTC

    Bristol Myers Squibb announced a dividend.

    Source:

  • Sep 15, 2026, 13:00 UTC

    Dr. Reddy's Laboratories launched NIVORZ, a nivolumab biosimilar of Bristol Myers Squibb's Opdivo, in India across 12 cancer indications, marking its entry into immuno-oncology.

    Source:

  • Sep 8, 2026, 10:59 UTC

    Bristol-Myers Squibb announced positive topline results from its registrational Phase 2 QUINTESSENTIAL trial for a potential first-in-class drug.

    Source:

  • Aug 29, 2026, 23:45 UTC

    RayzeBio Inc., a subsidiary of Bristol Myers Squibb, announced plans to build a new 225,000 square-foot radiopharmaceutical manufacturing facility in Whitestown, Indiana, with construction expected to begin this year and completion by the end of 2029.

    Source:

  • Aug 25, 2026, 15:35 UTC

    Bristol-Myers Squibb confirmed it has terminated its partnership with Cellares.

    Source:

  • Aug 24, 2026, 08:03 UTC

    Barbara Oil Co. acquired a new stake of 42,000 shares in Bristol Myers Squibb Company during the second quarter, as disclosed in its 13F filing.

    Source:

  • Aug 22, 2026, 08:05 UTC

    Blue Capital Inc. acquired a new position of 18,381 shares in Bristol Myers Squibb Company during the second quarter, valued at approximately $1,059,000, as disclosed in a recent SEC filing.

    Source:

  • Aug 20, 2026, 13:01 UTC

    Bristol-Myers Squibb will use Chai's AI model to aid antibody discovery.

    Source:

  • Aug 18, 2026, 16:15 UTC

    Biokin Pharma announced that its bispecific ADC iza-bren met the primary endpoint in the Panku-Lung01 phase 3 lung cancer trial, showing significant progression-free survival benefit.

    Source:

  • Aug 14, 2026, 12:03 UTC

    The U.S. Food and Drug Administration approved Bristol Myers Squibb's oral drug iberdomide (brand name Zenbexus) for advanced multiple myeloma, marking the debut of a new drug class and the first approval using a more sensitive remission measure.

    Source:

  • Aug 13, 2026, 20:26 UTC

    The U.S. FDA approved Bristol Myers Squibb's combination treatment for patients with a rare form of blood cancer whose illness had relapsed or not responded to other treatments.

    Source:

  • Aug 13, 2026, 16:45 UTC

    A U.S. federal appeals court revived a $6.7 billion lawsuit against Bristol Myers Squibb, ruling that a lower court erred in dismissing claims that the company delayed federal approval for three drugs, including the cancer treatment Breyanzi, to cheat former Celgene shareholders.

    Source:

  • Aug 13, 2026, 13:31 UTC

    Cytokinetics filed a patent infringement lawsuit against Bristol-Myers Squibb.

    Source:

  • Aug 10, 2026, 13:01 UTC

    Bristol Myers Squibb announced a $2.3 billion investment to build a new manufacturing campus in Houston, Texas, advancing its U.S. manufacturing expansion.

    Source:

  • Aug 5, 2026, 14:01 UTC

    AstraZeneca shares rose about 6% on Wednesday after Reuters reported there are no merger discussions with Bristol Myers Squibb, easing investor concerns.

    Source:

  • Aug 2, 2026, 19:36 UTC

    AstraZeneca has held talks with Bristol Myers Squibb about a potential merger, as reported by the Financial Times on Sunday.

    Source:

  • Jul 24, 2026, 20:45 UTC

    Bristol Myers Squibb announced it will deploy eight Nvidia DGX Vera Rubin NVL72 systems for AI-driven drug discovery and development.

    Source:

  • Jul 20, 2026, 10:59 UTC

    Bristol Myers Squibb announced a partnership with NVIDIA to build the most powerful AI factory in life sciences.

    Source:
← PreviousPage 2Next →